Biomarker analysis for high-risk stage I NSCLCs

Not Applicable

• Conditions: non-squamous NSCLC with pathological stage I disease; surgically-resected non-squamous NSCLC; D002289

• Registration Number: JPRN-jRCT1050220114
• Lead Sponsor: Suda Kenichi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

Non-squamous NSCLC patients who received R0 resection
Pure solid tumor at preoperative CT examination
Patients who received lobectomy and mediastinal LN dissection
Pathologically confirmed stage I NSCLC
RNA sample is available (cohort 1)
RNA sequence data is available (cohort 2)
FFPE sample is available (cohort 3)

Exclusion Criteria

Patients who received neoadjuvant therapy
Patients who died due to postoperative complication within 90 days after pulmonary resection
Patients with lost follow up within 5 years
In cohort3, patients who were enrolled in cohort 1 or cohort 2 will be excluded

Study & Design

• Study Type: Observational
• Study Design: Not specified